Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Leukemia and Lymphoma

• Publication date

  2007-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/10428190701190169PMID 17454628
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours

  2005cited by this paper
• A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar Trihydrochloride (LY335979), Administered Intravenously in Combination with Doxorubicin in Patients with Advanced Malignancy

  2004cited by this paper
• Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine.

  2004cited by this paper
• The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice

  2004cited by this paper
• Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995).

  2004cited by this paper
• Phase I Study of Docetaxel in Combination with the P-Glycoprotein Inhibitor, Zosuquidar, in Resistant Malignancies

  2004cited by this paper
• Population pharmacokinetic model for daunorubicin and daunorubicinol coadministered with zosuquidar.3HCl (LY335979)

  2004cited by this paper
• A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy.

  2004cited by this paper
• A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979)

  2003cited by this paper
• Modulation of P‐glycoprotein but not MRP1‐ or BCRP‐mediated drug resistance by LY335979

  2003cited by this paper
• Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia

  2002cited by this paper
• CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

  2002cited by this paper
• Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720.

  2002cited by this paper
• CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

  2002cited by this paper
• p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas.

  2002cited by this paper
• Intensification of salvage treatment with high‐dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non‐Hodgkin's lymphoma

  2001cited by this paper
• High expression of MDR‐1 gene and P‐glycoprotein in initial and re‐biopsy specimens of relapsed B‐cell lymphoma

  2001cited by this paper
• A family of drug transporters: the multidrug resistance-associated proteins.

  2000cited by this paper
• P-Glycoprotein Expression and Multidrug Resistance in Cutaneous T-cell Lymphoma

  2000cited by this paper
• MDR1/P-GP expression as a prognostic factor in acute leukemias.

  1999cited by this paper
• Multidrug resistance in aggressive lymphoproliferative disorders of T and natural-killer origin.

  1998cited by this paper
• Alternative (non-P-glycoprotein) mechanisms of drug resistance in non-Hodgkin's lymphoma.

  1997influential reference
• CHOP vs. ProMACE‐CytaBOM in the treatment of aggressive non‐Hodgkin's lymphomas: long‐term results of a multicenter randomized trial

  1996cited by this paper
• A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study.

  1994cited by this paper
• Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma.

  1992cited by this paper
• Advanced diffuse histiocytic lymphoma, a potentially curable disease.

  1975cited by this paper

• Magnolol derivatives as specific and noncytotoxic inhibitors of breast cancer resistance protein (BCRP/ABCG2).

  2024cites this paper
• The Impacts and Changes Related to the Cancer Drug Resistance Mechanism.

  2023cites this paper
• Recent Advances in Doxorubicin Formulation to Enhance Pharmacokinetics and Tumor Targeting

  2023cites this paper
• The HIV protease inhibitor, ritonavir, corrects diverse brain phenotypes across development in mouse model of DYT-TOR1A dystonia

  2021cites this paper
• Oral etoposide and zosuquidar bioavailability in rats: Effect of co-administration and in vitro-in vivo correlation of P-glycoprotein inhibition

  2021influential citation
• Role of ATP-Binding Cassette Transporter Proteins in CNS tumors: Resistance-based perspectives and clinical updates.

  2020cites this paper
• ABC Transporter-Mediated Multidrug-Resistant Cancer.

  2019cites this paper
• Chemoresistance mechanisms of breast cancer and their countermeasures.

  2019cites this paper
• Reversal of multidrug resistance by icaritin in doxorubicin-resistant human osteosarcoma cells.

  2018cites this paper
• Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine

  2018cites this paper
• The therapeutic potential of targeting ABC transporters to combat multi-drug resistance

  2017cites this paper
• 2‐Trifluoromethyl‐2‐Hydroxypropionamide Derivatives as Novel Reversal Agents of ABCG2 (BCRP)‐Mediated Multidrug Resistance: Synthesis and Biological Evaluations

  2017cites this paper
• Clinical Implications of P-Glycoprotein Modulation in Drug–Drug Interactions

  2017cites this paper
• Turning the gun on cancer: Utilizing lysosomal P-glycoprotein as a new strategy to overcome multi-drug resistance.

  2016cites this paper
• Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies.

  2016cites this paper
• Synthesis, Antiproliferative, and Multidrug Resistance Reversal Activities of Heterocyclic α,β‐Unsaturated Carbonyl Compounds

  2016cites this paper
• Reversal effect of ouabain on multidrug resistance in esophageal carcinoma EC109/CDDP cells by inhibiting the translocation of Wnt/β-catenin into the nucleus

  2016cites this paper
• Novel delivery approaches for cancer therapeutics.

  2015cites this paper
• Changed expression and function of P-gp in peripheral blood CD56 + cells predicting chemoresistance in non-Hodgkin lymphoma patients

  2015cites this paper
• Triggering of Suicidal Erythrocyte Death by Zosuquidar

  2015cites this paper
• The reversal of antineoplastic drug resistance in cancer cells by β-elemene

  2015cites this paper
• Icariin enhances cytotoxicity of doxorubicin in human multidrug-resistant osteosarcoma cells by inhibition of ABCB1 and down-regulation of the PI3K/Akt pathway.

  2015cites this paper
• Development of Fourth Generation ABC Inhibitors from Natural Products: A Novel Approach to Overcome Cancer Multidrug Resistance.

  2015cites this paper
• The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade.

  2015cites this paper
• P-gp Inhibitory Activity from Marine Sponges, Tunicates and Algae

  2015cites this paper
• Nanomedicine to overcome cancer multidrug resistance.

  2014cites this paper
• Physiological modulation approaches to improve cancer chemotherapy : a review.

  2014cites this paper
• ABC Transporters: Involvement in Multidrug Resistance and Drug Disposition

  2014cites this paper
• A novel compound RY10-4 downregulates P-glycoprotein expression and reverses multidrug-resistant phenotype in human breast cancer MCF-7/ADR cells.

  2014cites this paper
• Role of Membrane Transporters in Drug Delivery, Drug Disposition And Drug-Drug Interactions

  2014cites this paper
• Combined treatment of canine osteosarcoma cells with gene knock-down and chemotherapy

  2014cites this paper
• DMPPQA, a novel angiogenesis inhibitor, induces apoptosis in human colon cancer HCT‐116 cells and HUVECs

  2014cites this paper
• β-Elemene, a compound derived from Rhizoma zedoariae, reverses multidrug resistance mediated by the ABCB1 transporter.

  2014cites this paper
• Pharmacogenetic considerations for non-Hodgkin's lymphoma

  2013cites this paper
• Pharmacogenetic considerations for non-Hodgkin's lymphoma therapy

  2013cites this paper
• A P-gp vesicular transport inhibition assay - optimization and validation for drug-drug interaction testing.

  2013cites this paper
• Increased expression and function of P-glycoprotein in peripheral blood CD56+ cells is associated with the chemoresistance of non-small-cell lung cancer

  2012cites this paper
• Three decades of P-gp inhibitors: skimming through several generations and scaffolds.

  2012cites this paper
• IMPROVED DELIVERY OF MOLECULARLY TARGETED AGENTS UPON MODULATION OF MULTIDRUG RESISTANCE EFFLUX PROTEINS AT MOUSE BLOOD BRAIN BARRIER

  2012cites this paper
• ABC Drug Transporters and Their Impact on Drug Disposition/Drug Sensitivity and Resistance

  2012cites this paper
• Delivery of P-glycoprotein substrates using chemosensitizers and nanotechnology for selective and efficient therapeutic outcomes.

  2012cites this paper
• Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin

  2012cites this paper
• Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit?

  2012cites this paper
• Reversal of P-gp and MRP1-mediated multidrug resistance by H6, a gypenoside aglycon from Gynostemma pentaphyllum, in vincristine-resistant human oral cancer (KB/VCR) cells.

  2012cites this paper
• Bioengineering approaches to study multidrug resistance in tumor cells.

  2011cites this paper
• The controversial role of ABC transporters in clinical oncology.

  2011cites this paper
• Revisiting the ABCs of multidrug resistance in cancer chemotherapy.

  2011cites this paper
• Roles of sildenafil in enhancing drug sensitivity in cancer.

  2011cites this paper
• Improving cancer chemotherapy with modulators of ABC drug transporters.

  2011cites this paper
• Using Rhodamine 123 Accumulation in CD8+ Cells as a Surrogate Indicator to Study the P-Glycoprotein Modulating Effect of Cepharanthine Hydrochloride In Vivo

  2011cites this paper
• A novel indirubin derivative PHII-7 potentiates adriamycin cytotoxicity via inhibiting P-glycoprotein expression in human breast cancer MCF-7/ADR cells.

  2011cites this paper
• P-glycoprotein inhibition: the past, the present and the future.

  2011cites this paper
• Interaction of phenothiazines, stilbenes and flavonoids with multidrug resistance-associated transporters, P-glycoprotein and MRP1.

  2011cites this paper
• Reversing agents for ATP-binding cassette drug transporters.

  2010cites this paper
• Phase I study of valspodar (PSC‐833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: A report from the Children's Oncology Group

  2010cites this paper
• Perspectives of P-glycoprotein modulating agents in oncology and neurodegenerative diseases: pharmaceutical, biological, and diagnostic potentials.

  2010cites this paper
• Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function.

  2009cites this paper
• ACTIVE TRANSPORT AND CNS DELIVERY OF NOVEL TYROSINE

  2009cites this paper
• A Phase I Study of the P-Glycoprotein Antagonist Tariquidar in Combination with Vinorelbine

  2009cites this paper
• Multi‐Drug‐Resistance‐Reverting Agents: 2‐Aryloxazole and 2‐Arylthiazole Derivatives as Potent BCRP or MRP1 Inhibitors

  2009cites this paper
• Second-line treatment paradigms for diffuse large B-cell lymphomas

  2009cites this paper
• The issue of refractory disease in follicular and other lymphoma subtypes

  2009cites this paper
• Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma.

  2009cites this paper
• Chemotherapy in Mouse Models of Neuroblastoma Inhibitor Reversan Increases the Therapeutic Index of Associated Protein 1 − Small-Molecule Multidrug Resistance

  2009cites this paper
• Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance.

  2009cites this paper
• Identification of genes that confer tumor cell resistance to the Aurora B kinase inhibitor, AZD1152

  2009cites this paper
• Therapeutic potential of RNA interference in drug-resistant cancers.

  2009cites this paper
• A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen

  2009cites this paper
• Antitumour properties of acridone alkaloids on a murine lymphoma cell line.

  2008cites this paper
• Synthesis and biological evaluation of (hetero)arylmethyloxy- and arylmethylamine-phenyl derivatives as potent P-glycoprotein modulating agents.

  2008cites this paper
• New-generation efflux pump inhibitors

  2008cites this paper
• Development of inhibitors of ATP-binding cassette drug transporters – present status and challenges

  2008cites this paper
• 4‐Amino‐3‐acetylquinoline‐induced apoptosis of murine L1210 leukemia cells involves ROS‐mitochondrial‐mediated death signaling and activation of p38 MAPK

  2008cites this paper
• 4-Biphenyl and 2-naphthyl substituted 6,7-dimethoxytetrahydroisoquinoline derivatives as potent P-gp modulators.

  2008cites this paper
• An overview of cancer multidrug resistance: a still unsolved problem

  2008cites this paper
• Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML)

  2008cites this paper
• Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies.

  2008cites this paper
• Implications of ABC transporters on the disposition of typical veterinary medicinal products.

  2008cites this paper
• 2-[(3-Methoxyphenylethyl)phenoxy]-based ABCB1 inhibitors: effect of different basic side-chains on their biological properties.

  2008cites this paper
• Multidrug resistance in lymphoma: Is it time for clinical trials?

  2007cites this paper
• Recent advances in P-glycoprotein-mediated multidrug resistance reversal mechanisms.

  2007cites this paper
• Mini Review Article

  year unknowncites this paper